In this regard, dupilumab (Dupixent®), a fully human monoclonal antibody inhibiting the interleukin (IL)-4/IL-13 signaling through the blockade of the IL-4 receptor α subunit, has been recently approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of patients with moderate-to-severe inadequately controlled AD [6]. Here, IL13 is linked to Alzheimer disease.